Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

7. Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended		7 Months Ended	9 Months Ended
7. Stockholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Jul. 19, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Dividends earned	$ 0	$ 268,927		$ 0	$ 1,589,321
Stock issued for services, value				$ 9,310
Unrecognized compensation cost amortization period				1 year 4 months 10 days
Gain on change in fair value of warrants	2,087,041	$ 190,000		$ 6,813,701	190,000
Proceeds from sale of stock			$ 7,300,000	7,521,036	0
Stock Options [Member]
Unrecognized compensation cost	400,000			$ 400,000
Unrecognized compensation cost amortization period				1 year 7 months 2 days
Options granted				20,798,500
Cashless Exercise of Warrants [Member]
Stock issued for conversion of securities, shares issued				48,783
Previously Converted Preferred Stock [Member]
Stock issued for conversion of securities, shares issued				50,606
Public Offering [Member]
Stock issued new, shares				19,115,000
Proceeds from sale of stock				$ 7,500,000
Public Offering [Member] \| Overallotments [Member]
Warrants Issued				303,633
Medytox [Member] \| Common stock to employees and consultants [Member]
Share based compensation expense					2,900,000
Medytox [Member] \| Outstanding options [Member]
Share based compensation expense					500,000
Warrant Exercises [Member]
Stock issued for warrants exercised				43,809
Previously converted preferred stock [Member]
Shares issued in adjustment of prior conversion of preferred stock, shares				50,606
Previously issued to employee [Member]
Stock cancelled, shares				40,964
Epinex Diagnostics [Member]
Stock cancelled, shares				45,000
Consultant [Member]
Stock issued for services, shares issued				13,300
Stock issued for services, value				$ 9,310
Three Officers [Member]
Stock issued for compensation, shares				583,335
Employee [Member]
Share based compensation expense				$ 200,000
Restricted stock granted				83,334
Employees, Directors and Consultants [Member]
Share based compensation expense				$ 700,000
Employees, Directors and Consultants [Member] \| May 2, 2016 [Member]
Options granted				15,643,000
Employees, Directors and Consultants [Member] \| July 17, 2016 [Member]
Options granted				5,155,500
Medytox Series B Preferred Stock [Member]
Dividends earned					$ 1,600,000
Accrued dividends	$ 100,000			$ 100,000		$ 2,100,000
Preferred stock converted into common, common shares issued					5,733,945
Series C Preferred Stock [Member]
Preferred stock converted into common, preferred shares converted				260
Preferred stock converted into common, common shares issued				167,743
Series C Preferred Stock [Member] \| Exchange Agreement [Member]
Preferred stock converted into common, preferred shares converted				8,740
Warrants exchanged				6,451,613
Series G Preferred Stock [Member]
Preferred stock converted into common, preferred shares converted				4,182
Preferred stock converted into common, common shares issued				9,292,905
Series G Preferred Stock [Member] \| Exchange Agreement [Member]
Preferred stock converted into common, common shares issued				13,793
Exhange warrants issued				10,249,517
Warrant conversion price	$ .45			$ .45
Gain on change in fair value of warrants				$ 1,700,000